株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鬱病治療薬の世界市場:2015〜2019年

Global Depression Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 294938
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
鬱病治療薬の世界市場:2015〜2019年 Global Depression Drugs Market 2015-2019
出版日: 2015年06月10日 ページ情報: 英文 107 Pages
概要

WHOによる2008年のレポートによると、鬱病は男女問わず発症しますが、男性より女性の方がかかりやすいといわれています。米国では10人に1人が鬱病になり、18歳以上では1,480万人が患っているといわれています。世界の鬱病治療薬市場は、2014〜2019年にかけCAGR5.25%で拡大すると予測されています。

当レポートでは、世界の鬱病治療薬市場について詳細に分析し、市場の動向と2015〜2019年の成長見通し、パイプライン動向、作用機序別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 当レポートの範囲

第4章 製品プロファイル

第5章 市場調査方法

第6章 イントロダクション

第7章 疾患の概要

  • 鬱病の種類
  • 病因
  • 疫学
  • 治療と管理
  • 経済的負担

第8章 市場環境

  • 市場概要
  • 市場規模と予測
  • 2014〜2019年の米国の鬱病治療薬市場
  • ファイブフォース分析

第9章 作用機序別市場セグメンテーション

第10章 地域別セグメンテーション

第11章 パイプラインポートフォリオ

  • 後期パイプライン分子に関する重要情報

第12章 購入基準

第13章 市場成長促進因子

第14章 促進因子とその影響

第15章 市場の課題

第16章 促進因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー環境

  • 競合シナリオ
  • 市場シェア調査:2014年
  • その他の将来的見込みのあるベンダー

第20章 主要ベンダー調査

  • Actavis
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

第21章 当シリーズの他のレポート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR6053

About depression drugs

According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly categorized into six different types. An individual with severe depression can have suicidal thoughts and behaviors. According to a 2012 estimate by the WHO, about 3,000 suicides take place each day, resulting in more than a million deaths each year. Depression can be recurrent and can be severely debilitating. Patients with mild depression can be treated with medications, but in cases of moderate or severe depression, the patient needs both medication and professional psychotherapy in the form of counseling. According to a 2008 report by the WHO, depression affects men and women equally, but women are more likely to be affected by depression than men. According to the CDC, depression can lead to many adverse behaviors in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, in the US, one in every 10 individuals is affected by depression. According to the NIMH in the US, major depressive disorder is one of the most debilitating disorders in the US and affects about 14.80 million adults aged 18 years and above.

Technavio's analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global depression drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of depression. The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below:

  • Tricyclic antidepressants
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • Monoamine oxidase inhibitors
  • Others

Technavio's report, Global Depression Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Actavis
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Addex Therapeutics
  • Alkermes
  • AstraZeneca
  • Aurobindo Pharma
  • Avanir Pharmaceuticals
  • Cerecor
  • Chugai Pharmaceutical
  • Dart NeuroScience
  • Dr. Reddy's Laboratories
  • Edgemont Pharmaceuticals
  • E-Therapeutics
  • Euthymics
  • Evotec
  • F. Hoffmann-La Roche
  • Fabre Kramer
  • Gedeon Richter
  • H. Lundbeck
  • Intra-Cellular Therapies
  • Janssen Pharmaceuticals
  • Lupin
  • Luye Pharma
  • MSI Methylation Sciences
  • Naurex
  • Neuralstem
  • Novartis
  • Opko Health
  • Otsuka Pharmaceutical
  • Pierre Fabre
  • Shire
  • SK Biopharmaceuticals
  • Somerset Pharmaceuticals
  • Sun Pharmaceutical
  • Sunovion Pharmaceuticals
  • Suven
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Torrent Pharmaceuticals
  • Valeant Pharmaceuticals

Market driver

  • Rise in patient population
  • For a full, detailed list, view our report

Market challenge

  • Threat of expiry of patents
  • For a full, detailed list, view our report

Market trend

  • Growing public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Product Profiles

    • 04.1.1. Celexa
    • 04.1.2. Fetzima
    • 04.1.3. Lexapro
    • 04.1.4. Viibryd
    • 04.1.5. Cymbalta
    • 04.1.6. Prozac
    • 04.1.7. Symbyax
    • 04.1.8. Paxil
    • 04.1.9. Wellbutrin
    • 04.1.10. Abilify
    • 04.1.11. Effexor
    • 04.1.12. Pristiq
    • 04.1.13. Zoloft

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disorder Overview

  • 07.1. Types of depression
    • 07.1.1. Major depressive disorder
    • 07.1.2. Persistent depressive disorder
    • 07.1.3. Psychotic depression
    • 07.1.4. Postpartum depression
    • 07.1.5. Seasonal affective disorder
    • 07.1.6. Bipolar disorder
  • 07.2. Etiology
  • 07.3. Epidemiology
    • 07.3.1. Bipolar disorder among adults
    • 07.3.2. Dysthymic disorder among adults
    • 07.3.3. Major depression among adults
    • 07.3.4. Major depression among adolescents
  • 07.4. Treatment and management
  • 07.5. Economic burden

08. Market Landscape

  • 08.1. Market overview
  • 08.2. Market size and forecast
  • 08.3. Depression drugs market in US 2014-2019
    • 08.3.1. Market size and forecast
  • 08.4. Five forces analysis

09. Market Segmentation by Mechanism of Action

10. Geographical Segmentation

  • 10.1. Segmentation of global depression drugs market by geography 2014

11. Pipeline Portfolio

  • 11.1. Key information on late-stage pipeline molecules
    • 11.1.1. Brexpiprazole
    • 11.1.2. ALKS 5461
    • 11.1.3. Cariprazine
    • 11.1.4. TGFK07AD

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive scenario
    • 19.1.1. Key news
    • 19.1.2. Mergers and acquisitions
  • 19.2. Market share analysis 2014
    • 19.2.1. Competitive assessment of top drugs used for treating depression
    • 19.2.2. Bristol-Myers Squibb
    • 19.2.3. Eli Lilly
    • 19.2.4. Pfizer
    • 19.2.5. GlaxoSmithKline
    • 19.2.6. Actavis
  • 19.3. Other and future prominent vendors

20. Key Vendor Analysis

  • 20.1. Actavis
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Segmentation by Revenue 2012 and 2013
    • 20.1.5. Geographical segmentation by Sales 2013
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Bristol-Myers Squibb
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Key Product Offerings
    • 20.2.4. Revenue by Geography
    • 20.2.5. Business Strategy
    • 20.2.6. Key Information
    • 20.2.7. SWOT Analysis
  • 20.3. Eli Lilly
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation by Revenue
    • 20.3.4. Sales by Geography
    • 20.3.5. Business Strategy
    • 20.3.6. Key Information
    • 20.3.7. SWOT Analysis
  • 20.4. GlaxoSmithKline
    • 20.4.1. Key facts
    • 20.4.2. Business overview
    • 20.4.3. Business segmentation by revenue 2014
    • 20.4.4. Business segmentation by revenue 2013 and 2014
    • 20.4.5. Geographical segmentation by revenue 2014
    • 20.4.6. Business strategy
    • 20.4.7. Recent developments
    • 20.4.8. SWOT analysis
  • 20.5. Pfizer
    • 20.5.1. Key facts
    • 20.5.2. Business overview
    • 20.5.3. Business segmentation by revenue 2014
    • 20.5.4. Business segmentation by revenue 2013 and 2014
    • 20.5.5. Geographical segmentation by revenue 2014
    • 20.5.6. Business strategy
    • 20.5.7. Key developments
    • 20.5.8. SWOT analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: NIMH classification of depression
  • Exhibit 3: Prevalence data for major depressive disorder among adults in US (2012)
  • Exhibit 4: Prevalence data for dysthymic disorder among adults in US (2012)
  • Exhibit 5: 12-month prevalence data for major depressive disorder with severe impairment among adults in US (2012)
  • Exhibit 6: Prevalence data for major depressive disorder among adults in US (2012)
  • Exhibit 7: Prevalence data for major depression among adults in US (2012)
  • Exhibit 8: WHO guidelines for management of depression
  • Exhibit 9: Economic burden of depression in US
  • Exhibit 10: Segmentation of costs associated with depression
  • Exhibit 11: Snapshot of economic burden of depression in US
  • Exhibit 12: Global depression drugs market 2014-2019 ($ millions)
  • Exhibit 13: Depression drugs market in US 2014-2019 ($ millions)
  • Exhibit 14: Segmentation of global depression drugs market by mechanism of action
  • Exhibit 15: Segmentation of global depression drugs market by mechanism of action 2014
  • Exhibit 16: Segmentation of global depression drugs market by geography 2014
  • Exhibit 17: Depression drugs: pipeline portfolio
  • Exhibit 18: Vendor ranking 2014
  • Exhibit 19: YoY growth rate of major depression drugs 2010-2014 ($ millions)
  • Exhibit 20: Revenue comparison of top drugs used for treating depression in 2013 ($ millions)
  • Exhibit 21: YoY global revenue of Abilify 2010-2014 ($ millions)
  • Exhibit 22: YoY global revenue of Cymbalta 2010-2014 ($ millions)
  • Exhibit 23: YoY global revenue of Pristiq 2010-2014 ($ millions)
  • Exhibit 24: YoY global revenue of Zoloft 2010-2014 ($ millions)
  • Exhibit 25: YoY global revenue of Effexor 2010-2014 ($ millions)
  • Exhibit 26: YoY global revenue of Wellbutrin 2010-2013 ($ millions)
  • Exhibit 27: YoY revenue of Wellbutrin in US 2010-2013 ($ millions)
  • Exhibit 28: YoY global revenue of Paxil 2010-2014 ($ millions)
  • Exhibit 29: Actavis: Business Segmentation
  • Exhibit 30: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 31: Actavis: Geographical segmentation by Sales 2013
  • Exhibit 32: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 33: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 34: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 35: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 36: Eli Lilly: Sales by Geography 2013
  • Exhibit 37: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 38: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 39: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 40: Pfizer: Business segmentation by revenue 2014
  • Exhibit 41: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 42: Pfizer: Geographical segmentation by revenue 2014
Back to Top